G
Giuseppe Masucci
Researcher at Karolinska Institutet
Publications - 137
Citations - 10026
Giuseppe Masucci is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 44, co-authored 133 publications receiving 8766 citations. Previous affiliations of Giuseppe Masucci include German Cancer Research Center & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pagès,Bernhard Mlecnik,Florence Marliot,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Fang Shu Ou,Carlo Bifulco,Alessandro Lugli,Inti Zlobec,Tilman T. Rau,Martin D. Berger,Iris D. Nagtegaal,Elisa Vink-Börger,Arndt Hartmann,Carol Geppert,Julie Kolwelter,Susanne Merkel,Robert Grützmann,Marc Van den Eynde,Anne Jouret-Mourin,Alex Kartheuser,Daniel Léonard,Christophe Remue,Julia Y. Wang,Julia Y. Wang,Prashant Bavi,Michael H.A. Roehrl,Michael H.A. Roehrl,Michael H.A. Roehrl,Pamela S. Ohashi,Linh T. Nguyen,Seong Jun Han,Heather L. MacGregor,Sara Hafezi-Bakhtiari,Bradly G. Wouters,Giuseppe Masucci,Emilia Andersson,Eva Zavadova,Michal Vocka,Jan Spacek,Lubos Petruzelka,Bohuslav Konopasek,Pavel Dundr,Helena Skalova,Kristyna Nemejcova,Gerardo Botti,Fabiana Tatangelo,Paolo Delrio,Gennaro Ciliberto,Michele Maio,Luigi Laghi,Fabio Grizzi,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Bénédicte Buttard,Bénédicte Buttard,Bénédicte Buttard,Mihaela Angelova,Mihaela Angelova,Mihaela Angelova,Angela Vasaturo,Angela Vasaturo,Angela Vasaturo,Pauline Maby,Pauline Maby,Pauline Maby,Sarah E. Church,Helen K. Angell,Lucie Lafontaine,Lucie Lafontaine,Lucie Lafontaine,Daniela Bruni,Daniela Bruni,Daniela Bruni,Carine El Sissy,Nacilla Haicheur,Amos Kirilovsky,Anne Berger,Christine Lagorce,Jeffrey P. Meyers,Christopher Paustian,Zipei Feng,Carmen Ballesteros-Merino,Jeroen R. Dijkstra,Carlijn van de Water,Shannon van Vliet,Nikki Knijn,Ana Maria Mușină,Dragos Viorel Scripcariu,Boryana Popivanova,Mingli Xu,Tomonobu Fujita,Shoichi Hazama,Nobuaki Suzuki,Hiroaki Nagano,Kiyotaka Okuno,Toshihiko Torigoe,Noriyuki Sato,Tomohisa Furuhata,Ichiro Takemasa,Kyogo Itoh,P. Patel,Hemangini H. Vora,Birva Shah,Jayendrakumar B. Patel,Kruti N. Rajvik,Shashank J. Pandya,Shilin N. Shukla,Yili Wang,Guanjun Zhang,Yutaka Kawakami,Francesco M. Marincola,Paolo A. Ascierto,Daniel J. Sargent,Bernard A. Fox,Bernard A. Fox,Jérôme Galon,Jérôme Galon,Jérôme Galon +120 more
TL;DR: The immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer and supports the implementation of the consensus Immunoscore as a new component of a TNM-Immune classification of cancer.
Journal ArticleDOI
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
Jérôme Galon,Jérôme Galon,Jérôme Galon,Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Helen K. Angell,Helen K. Angell,Helen K. Angell,Anne Berger,Christine Lagorce,Alessandro Lugli,Inti Zlobec,Arndt Hartmann,Carlo Bifulco,Iris D. Nagtegaal,Richard Palmqvist,Giuseppe Masucci,Gerardo Botti,Fabiana Tatangelo,Paolo Delrio,Michele Maio,Luigi Laghi,Fabio Grizzi,Martin Asslaber,Corrado D'Arrigo,Fernando Vidal-Vanaclocha,Eva Zavadova,Lotfi Chouchane,Pamela S. Ohashi,Sara Hafezi-Bakhtiari,Bradly G. Wouters,Michael H.A. Roehrl,Linh V. Nguyen,Yutaka Kawakami,Shoichi Hazama,Kiyotaka Okuno,Shuji Ogino,Peter Gibbs,Paul Waring,Noriyuki Sato,Toshihiko Torigoe,Kyogo Itoh,P. Patel,Shilin N. Shukla,Yili Wang,Scott Kopetz,Frank A. Sinicrope,Viorel Scripcariu,Paolo A. Ascierto,Francesco M. Marincola,Bernard A. Fox,Bernard A. Fox,Franck Pagès +56 more
TL;DR: In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC or UICCTNM classification.
Journal ArticleDOI
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Marie Marchand,N van Baren,N van Baren,P. Weynants,P. Weynants,Vincent Brichard,Vincent Brichard,Vincent Brichard,Brigitte Dreno,M H Tessier,E Rankin,Giorgio Parmiani,Flavio Arienti,Yves Humblet,A Bourlond,Romain Vanwijck,Danielle Lienard,Marc Beauduin,Pierre-Yves Dietrich,Vincenzo Russo,Joseph Kerger,Giuseppe Masucci,Elke Jäger,J. P. De Greve,J Atzpodien,Francis Brasseur,Francis Brasseur,Pierre Coulie,P. van der Bruggen,P. van der Bruggen,Thierry Boon,Thierry Boon +31 more
TL;DR: The results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
Journal ArticleDOI
Cancer classification using the Immunoscore: a worldwide task force
Jérôme Galon,Franck Pagès,Francesco M. Marincola,Francesco M. Marincola,Helen K. Angell,Helen K. Angell,Magdalena Thurin,Alessandro Lugli,Inti Zlobec,Anne Berger,Carlo Bifulco,Gerardo Botti,Fabiana Tatangelo,Cedrik M. Britten,Sebastian Kreiter,Lotfi Chouchane,Paolo Delrio,Hartmann Arndt,Martin Asslaber,Michele Maio,Giuseppe Masucci,Martin C. Mihm,Fernando Vidal-Vanaclocha,James P. Allison,Sacha Gnjatic,Leif Håkansson,Christoph Huber,Harpreet Singh-Jasuja,Christian H. Ottensmeier,Heinz Zwierzina,Luigi Laghi,Fabio Grizzi,Pamela S. Ohashi,Patricia Shaw,Blaise Clarke,Bradly G. Wouters,Yutaka Kawakami,Shoichi Hazama,Kiyotaka Okuno,Ena Wang,Jill O'Donnell-Tormey,Christine Lagorce,Graham Pawelec,Michael I. Nishimura,Robert E. Hawkins,Réjean Lapointe,Andreas Lundqvist,Samir N. Khleif,Shuji Ogino,Peter Gibbs,Paul Waring,Noriyuki Sato,Toshihiko Torigoe,Kyogo Itoh,P. Patel,Shilin N. Shukla,Richard Palmqvist,Iris D. Nagtegaal,Yili Wang,Corrado D'Arrigo,Scott Kopetz,Frank A. Sinicrope,Giorgio Trinchieri,Thomas F. Gajewski,Thomas F. Gajewski,Paolo A. Ascierto,Bernard A. Fox,Bernard A. Fox,Bernard A. Fox +68 more
TL;DR: Evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy, into traditional classification of cancer, designated TNM-I (TNM-Immune), and introduction of this parameter as a biomarker to classify cancers will facilitate clinical decision-making.
Journal ArticleDOI
Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
TL;DR: Examination of circulating CD14(+)HLA-DR(-/low) MDSC in 34 advanced malignant melanoma patients finds the coexpression of markers associated with mature phenotype and several observations suggest a redox imbalance in M DSC and indicate an important role of Stat3-dependent oxidative stress in MDSc-mediated T-cell suppression.